« Selective JAK1 Inhibition Using Upadacitinib for the Management of Inflammatory Bowel Diseases: The Powerful Pill ». Canadian IBD Today, vol. 1, nᵒ S11, novembre 2023, p. 2–11, https://doi.org/10.58931/cibdt.2023.1S1121.